Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

Univercells Technologies agreed to collaborate with Repligen to integrate real-time monitoring capabilities and enhance the development and manufacturing of viral vectors and vaccines. Repligen’s ...

Inspection reports obtained by ABC News show a series of quality control issues. Even as shots of the Johnson & Johnson COVID-19 vaccine resume across the country following a recent ...